Latest Commercial Operations News

Genmin Limited secures a A$2 million unsecured loan from its non-executive Chair to support working capital as it advances the Baniaka iron ore project in Gabon.

Silex Systems reports steady progress on its TRL-6 uranium enrichment demonstration, targeting completion by end-2025, while securing initial US government funding to support commercialisation efforts.

Nanoveu Limited has successfully raised $2.3 million through a share placement to accelerate development and commercialization of its cutting-edge semiconductor, 3D visualization, and solar coating technologies.

ReNu Energy has completed the sale of its hydrogen division and is set to acquire Janus Electric, a pioneer in electric truck battery swapping, backed by a substantial capital raise to scale operations.

Renascor Resources reports significant engineering advances that increase high-value graphite production by 60%, reduce operating costs, and confirm a safer, eco-friendly purification process.

Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.

Austral Gold’s Q1 2025 report reveals a 15.4% drop in gold equivalent production at its Guanaco mine due to mine depletion and mill repairs, while refurbishment advances at Casposo aim to boost future output.

Challenger Gold Limited confirms steady progress on refurbishing the Casposo Toll Milling Plant in Argentina, with a second independent inspection validating the refurbishment is on track for commissioning in the second half of 2025.

MedAdvisor Limited reports a steep decline in 3Q FY25 revenue, driven by US market challenges, while accelerating cost-cutting and reaffirming full-year guidance.

EV Resources Limited advances its position in the critical antimony market with a 70% stake acquisition in Mexico’s Los Lirios project and full ownership of Utah’s historic Coyote Creek claims, setting the stage for exploration and development.

OncoSil Medical has reported a remarkable 233% increase in dose sales for Q3 FY25, alongside significant regulatory approvals and strategic expansions that position the company for accelerated growth.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.